Peregrine Capital Management LLC raised its holdings in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 3.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 68,390 shares of the company's stock after acquiring an additional 2,250 shares during the period. Peregrine Capital Management LLC owned about 0.20% of TransMedics Group worth $4,601,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. NBC Securities Inc. acquired a new stake in shares of TransMedics Group during the first quarter valued at about $25,000. Atlas Capital Advisors Inc. acquired a new stake in shares of TransMedics Group during the fourth quarter valued at about $31,000. AlphaQuest LLC acquired a new stake in shares of TransMedics Group during the fourth quarter valued at about $52,000. Rakuten Securities Inc. boosted its stake in shares of TransMedics Group by 68.3% during the fourth quarter. Rakuten Securities Inc. now owns 1,355 shares of the company's stock valued at $84,000 after purchasing an additional 550 shares in the last quarter. Finally, Sava Infond d.o.o. acquired a new stake in shares of TransMedics Group during the fourth quarter valued at about $94,000. Institutional investors own 99.67% of the company's stock.
Analysts Set New Price Targets
A number of analysts have recently commented on the company. Piper Sandler reissued an "overweight" rating and set a $145.00 price target (up from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Oppenheimer lifted their price target on TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Canaccord Genuity Group reissued a "buy" rating and set a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $127.33.
Check Out Our Latest Research Report on TMDX
Insider Buying and Selling at TransMedics Group
In other TransMedics Group news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the transaction, the director directly owned 732 shares of the company's stock, valued at approximately $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David Weill sold 732 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 12,418 shares of company stock valued at $1,512,613. 7.00% of the stock is currently owned by company insiders.
TransMedics Group Trading Up 0.8%
Shares of TransMedics Group stock traded up $1.04 during midday trading on Friday, reaching $128.73. The company had a trading volume of 369,545 shares, compared to its average volume of 1,370,815. The stock has a fifty day moving average price of $122.32 and a 200 day moving average price of $88.37. The company has a debt-to-equity ratio of 1.92, a current ratio of 9.10 and a quick ratio of 8.32. The firm has a market cap of $4.35 billion, a PE ratio of 94.65 and a beta of 2.06. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.29 by $0.41. TransMedics Group had a return on equity of 21.88% and a net margin of 10.03%. The firm had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same period in the previous year, the firm earned $0.35 earnings per share. The company's revenue was up 48.2% compared to the same quarter last year. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.
TransMedics Group Profile
(
Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Recommended Stories

Before you consider TransMedics Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.
While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.